RxDoctor Payments Data

Denise Chambers, PA

Medical · Huntington, WVNPI 1750574968

Payments from drug & device makers

$1,049in general payments, 2019–2025

Across 20 payments — averaging $52.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$461
  • Novo Nordisk$247
  • AbbVie$119
  • Johnson & Johnson$69
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$55
  • Abbott$22
  • plus $75 from 4 others

What the payments were for

  • Food & beverage$63861%
  • Education$41139%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,049 in reported general payments places this provider in the 55th percentile of 233 medical providers in West Virginia.

See all medical providers in West Virginia

Medicare billing

Part B allowed, 2024
$15,669
Medicare patients
93
Services billed
209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$36,843
Breo ElliptaFluticasone/Vilanterol38$16,912
MounjaroTirzepatide15$15,421
EliquisApixaban22$15,169
Spiriva HandihalerTiotropium Bromide13$7,252
MyrbetriqMirabegron11$5,543
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,691
SynthroidLevothyroxine Sodium13$1,416
Gabapentin83$1,130
Albuterol Sulfate HfaAlbuterol Sulfate32$774
Metoprolol Succinate81$697
Duloxetine Hcl55$672
Diclofenac Sodium14$620
Omeprazole84$613
Levothyroxine Sodium60$573

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$247$36,84334 claims
Lilly USA, LLCMounjaro$19$15,42115 claims
Astellas Pharma US IncMyrbetriq$18$5,54311 claims
AbbVieSynthroid$119$1,41613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 233 medical providers in West Virginia.

Other medical in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →